Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Clinical Immunology

Living with Protection: Antibody Replacement and Infection Control

At a Glance

Children with autosomal recessive agammaglobulinemia 7 need lifelong immunoglobulin replacement because their bodies cannot make protective antibodies. IVIG or SCIG supplies IgG, while a written fever plan helps caregivers respond quickly to breakthrough infections.

Because your child’s body cannot produce its own antibodies, they require lifelong immunoglobulin replacement therapy (IRT) [1][2]. This treatment provides your child with IgG (the most common type of antibody) collected from thousands of healthy donors, giving them the “borrowed” immunity they need to fight off bacteria and viruses [3][4].

Choosing the Right Route

There are two main ways your child can receive these life-saving antibodies. Neither is “better” for every child; the choice depends on your family’s lifestyle, your child’s veins, product availability in your country, and how they tolerate the medicine.

  • Intravenous Immunoglobulin (IVIG):

    • How it’s given: A nurse inserts a needle into a vein, and the medicine drips in over several hours. This is usually done in a hospital or infusion center on a schedule tailored to your child (commonly every 3 to 4 weeks) [5].
    • Pros and Cons: It requires fewer needles per month. However, it creates high “peaks” of antibodies right after the infusion and “troughs” (low points) just before the next one, which some children feel as a “wear-off” effect [5][6]. It also requires reliable venous access [7].

  • Subcutaneous Immunoglobulin (SCIG):

    • How it’s given: Using a small pump and tiny needles, the medicine is infused into the fatty tissue just under the skin (usually in the belly or thighs). Depending on the product, this is often done at home once a week [5][8].
    • Pros and Cons: It provides very steady antibody levels without the “peaks and troughs” of IVIG [9]. It does not require a vein. However, it requires more frequent needle sticks and detailed training for parents to do it safely at home [10][7].

A newer option, facilitated SCIG, uses an enzyme to help the body absorb a larger amount of medicine under the skin, allowing for home infusions less frequently. Note that facilitated SCIG is not appropriate or licensed for every age group or in every country, so discuss this with your immunologist [11][8].

Managing Side Effects

While IRT is generally safe, it can cause reactions. Knowing what to expect can help you stay calm and prepared.

  • Common Reactions: For IVIG, children may experience flu-like symptoms such as headache, fever, chills, or nausea during or after the infusion [5][12]. For SCIG, the most common side effect is local redness, swelling, or itching at the injection site, which usually fades within 24 hours [5][13].
  • Rare but Serious Risks: In very rare cases, IRT can cause more serious issues, including thrombosis (blood clots), renal injury (kidney issues), or aseptic meningitis (a severe, non-infectious headache and stiff neck) [14][15][16].
  • When to Act: Seek urgent medical help for breathing difficulty, facial swelling, collapse, chest pain, severe persistent headache, or markedly reduced urine. Never change or stop an infusion except under the infusion team’s direct instructions, unless it is a life-threatening emergency.

Infection Action Plans and Antibiotics

Even with perfect antibody levels, “breakthrough” infections can happen.

  • Action Plans, Not Assumptions: Never self-start antibiotics for a fever. Your child should have a specific fever/infection action plan created by their doctor detailing when to call, when to get cultures, and when to go to the ER. In some highly individualized cases, a doctor may provide a pre-authorized “standby” antibiotic prescription, but this must only be used exactly as directed by your care team [17][18].
  • Prophylactic Antibiotics: If your child continues to get frequent infections despite optimized IRT, or if they have lung damage, your doctor might discuss a daily, low-dose antibiotic (prophylaxis). This is an individualized option, not an expected routine second line for everyone [19][20][21].

Common questions in this guide

Why does a child with agammaglobulinemia 7 need immunoglobulin replacement?
Agammaglobulinemia prevents the body from making enough protective antibodies. Immunoglobulin replacement supplies donor IgG to help protect against bacterial and viral infections, and treatment is generally lifelong.
What is the difference between IVIG and SCIG for agammaglobulinemia?
IVIG delivers immunoglobulin into a vein, usually at an infusion center every three to four weeks. SCIG delivers it under the skin, often at home weekly, without needing reliable vein access. The best option depends on the child’s veins, tolerance, family routine, product availability, and training.
How often might my child receive IVIG or SCIG?
IVIG is commonly given every three to four weeks, while many SCIG products are given once a week. Facilitated SCIG may allow less frequent home infusions for some patients, but age limits and approval differ by product and country.
What side effects can happen during immunoglobulin treatment?
IVIG may cause headache, fever, chills, or nausea during or after an infusion. SCIG more often causes temporary redness, swelling, or itching where the medicine enters the skin. Breathing difficulty, facial swelling, collapse, chest pain, severe persistent headache, or much less urine requires urgent medical attention.
What should I do if my child develops a fever or breakthrough infection?
Follow the written fever and infection action plan from your child’s doctor, including instructions about calling the care team, obtaining cultures, or going to the emergency department. Do not start antibiotics on your own unless the care team has provided specific instructions for that situation.
Will my child need preventive antibiotics in addition to immunoglobulin replacement?
Not every child needs preventive antibiotics. An immunologist may consider a daily low-dose antibiotic if infections continue despite optimized immunoglobulin treatment or if lung damage is present. This decision is individualized and should be made with the child’s care team.

Get notified when new evidence is published on agammaglobulinemia 7, autosomal recessive.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Immunoglobulin replacement therapies in inborn errors of immunity: a review.

    Sil A, Basu S, Joshi V, et al.

    Frontiers in pediatrics 2024; (12()):1368755 doi:10.3389/fped.2024.1368755.

    PMID: 38425666
  2. 2

    X-linked agammaglobulinemia: ınvestigation of clinical and laboratory findings, novel gene mutations and prevention of ınfective complications in long-term follow-up.

    Yıldırım İ, Topyıldız E, Bilgin RBG, et al.

    American journal of clinical and experimental immunology 2021; (10(1)):37-43.

    PMID: 33815962
  3. 3

    Long-term follow-up of 168 patients with X-linked agammaglobulinemia reveals increased morbidity and mortality.

    Lougaris V, Soresina A, Baronio M, et al.

    The Journal of allergy and clinical immunology 2020; (146(2)):429-437 doi:10.1016/j.jaci.2020.03.001.

    PMID: 32169379
  4. 4

    Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.

    Sun D, Heimall JR, Greenhawt MJ, et al.

    JAMA pediatrics 2022; (176(2)):176-184 doi:10.1001/jamapediatrics.2021.4583.

    PMID: 34779842
  5. 5

    Intravenous and subcutaneous immunoglobulin G replacement therapy.

    Bonilla FA

    Allergy and asthma proceedings 2016; (37(6)):426-431 doi:10.2500/aap.2016.37.3987.

    PMID: 27931296
  6. 6

    Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies.

    Shrestha P, Karmacharya P, Wang Z, et al.

    The World Allergy Organization journal 2019; (12(10)):100068 doi:10.1016/j.waojou.2019.100068.

    PMID: 31641401
  7. 7

    The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.

    Lechanska-Helman J, Sobocinska A, Jerzynska J, Stelmach I

    Pediatrics international : official journal of the Japan Pediatric Society 2020; (62(3)):316-318 doi:10.1111/ped.14119.

    PMID: 31880367
  8. 8

    A clinician's guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.

    Epland K, Suez D, Paris K

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2022; (18(1)):87 doi:10.1186/s13223-022-00726-7.

    PMID: 36180928
  9. 9

    Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases.

    Navarro-Mora G, Alberti JJ, Mondou E, et al.

    International immunopharmacology 2022; (104()):108472 doi:10.1016/j.intimp.2021.108472.

    PMID: 35008008
  10. 10

    Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction.

    Mallick R, Hahn N, Scalchunes C

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (21(1)):2 doi:10.1186/s13223-024-00939-y.

    PMID: 39773529
  11. 11

    Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.

    Ponsford M, Carne E, Kingdon C, et al.

    Clinical and experimental immunology 2015; (182(3)):302-13 doi:10.1111/cei.12694.

    PMID: 26288095
  12. 12

    Characteristics of adverse events and clinical risks of intravenous immunoglobulin: a pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS).

    Lu Z, Lu X, Gao Y, et al.

    Frontiers in medicine 2025; (12()):1724196 doi:10.3389/fmed.2025.1724196.

    PMID: 41574383
  13. 13

    Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort.

    Yalcin Gungoren E, Yorgun Altunbas M, Dikici U, et al.

    Journal of clinical immunology 2024; (44(8)):169 doi:10.1007/s10875-024-01771-0.

    PMID: 39098942
  14. 14

    Adverse Reactions Associated with Intravenous Immunoglobulin Administration in the Treatment of Neurological Disorders: A Systematic Review.

    Jiang M, Kimber JS, Gupta A, et al.

    International archives of allergy and immunology 2023; (184(6)):513-528 doi:10.1159/000529110.

    PMID: 37015212
  15. 15

    Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.

    Lozeron P, Not A, Theaudin M, et al.

    Muscle & nerve 2016; (53(5)):683-9 doi:10.1002/mus.24942.

    PMID: 26467654
  16. 16

    Acute Aseptic Meningitis Temporally Associated with Intravenous Polyclonal Immunoglobulin Therapy: A Systematic Review.

    De Felice ELT, Toti GF, Gatti B, et al.

    Clinical reviews in allergy & immunology 2024; (66(2)):241-249 doi:10.1007/s12016-024-08989-1.

    PMID: 38739354
  17. 17

    Bruton's Agammaglobulinemia: Case Series and Literature Review From King Fahad Central Hospital, Jizan, Saudi Arabia.

    Shamakhi A, Dhayhi N, Matabi S, et al.

    The American journal of case reports 2025; (26()):e949936 doi:10.12659/AJCR.949936.

    PMID: 41391163
  18. 18

    Helicobacter cinaedi-Associated Refractory Cellulitis in Patients with X-Linked Agammaglobulinemia.

    Inoue K, Sasaki S, Yasumi T, et al.

    Journal of clinical immunology 2020; (40(8)):1132-1137 doi:10.1007/s10875-020-00830-6.

    PMID: 32914284
  19. 19

    Specific Antibody Deficiency: Controversies in Diagnosis and Management.

    Perez E, Bonilla FA, Orange JS, Ballow M

    Frontiers in immunology 2017; (8()):586 doi:10.3389/fimmu.2017.00586.

    PMID: 28588580
  20. 20

    Increased Respiratory Viral Detection and Symptom Burden Among Patients with Primary Antibody Deficiency: Results from the BIPAD Study.

    Ponsford MJ, Price C, Farewell D, et al.

    The journal of allergy and clinical immunology. In practice 2021; (9(2)):735-744.e6 doi:10.1016/j.jaip.2020.08.016.

    PMID: 32841749
  21. 21

    Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).

    Syed MN, Kutac C, Miller JM, et al.

    Journal of clinical immunology 2022; (42(7)):1545-1552 doi:10.1007/s10875-022-01317-2.

    PMID: 35779201

This page is for informational purposes only and does not constitute medical advice. Your child’s immunologist and infusion team should tailor immunoglobulin treatment, infection plans, and emergency instructions.

Guide contents agammaglobulinemia 7, autosomal recessive
Research & Literature
03 The Science of Diagnosis 05 Building Your Care Team